Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: CVAC (4-star) is a WEAK-BUY. BUY since 127 days. Simulated Profits (55.04%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.29
1 Year Target Price $5.29
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 85.02% | Avg. Invested days 59 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio 5.36 | 1Y Target Price 5.29 |
Price to earnings Ratio 5.36 | 1Y Target Price 5.29 | ||
Volume (30-day avg) 6 | Beta 2.51 | 52 Weeks Range 2.37 - 5.72 | Updated Date 10/27/2025 |
52 Weeks Range 2.37 - 5.72 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.93% | Operating Margin (TTM) -4959.44% |
Management Effectiveness
Return on Assets (TTM) 23.77% | Return on Equity (TTM) 40.22% |
Valuation
Trailing PE 5.36 | Forward PE 5.24 | Enterprise Value 791548926 | Price to Sales(TTM) 2.36 |
Enterprise Value 791548926 | Price to Sales(TTM) 2.36 | ||
Enterprise Value to Revenue 1.32 | Enterprise Value to EBITDA 2.83 | Shares Outstanding 225172749 | Shares Floating 125869315 |
Shares Outstanding 225172749 | Shares Floating 125869315 | ||
Percent Insiders 57.37 | Percent Institutions 6.54 |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV, founded in 2000 in Tu00fcbingen, Germany, is a biopharmaceutical company pioneering mRNA-based therapies. Initially focused on vaccine development, it has broadened its scope to include oncology and protein therapies. A significant milestone was its IPO on the Nasdaq in 2020.
Core Business Areas
- mRNA-Based Vaccines: Development of vaccines against infectious diseases using mRNA technology. This includes early-stage development of various prophylactic and therapeutic vaccines.
- mRNA-Based Cancer Immunotherapies: Using mRNA technology to develop immunotherapies for cancer treatment. This involves inducing an immune response against tumor-associated antigens.
- mRNA-Based Protein Therapies: Developing mRNA-encoded protein therapies to address a range of diseases, by enabling cells to produce therapeutic proteins.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceuticals. Organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- CVmRNA: CureVac's proprietary mRNA technology platform. Although the COVID-19 vaccine efforts were not successful in reaching its initial goals, this technology is the basis for all other research and development. Competitors include Moderna (MRNA) and BioNTech (BNTX).
- CvnCoV: COVID-19 vaccine candidate. This vaccine did not achieve the efficacy levels of competitors and its development has been deprioritized. Competitors include Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA).
Market Dynamics
Industry Overview
The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA COVID-19 vaccines. The industry is characterized by high innovation and competition.
Positioning
CureVac is a player in the mRNA space, but it has fallen behind market leaders. It needs to demonstrate success in its other programs to regain investor confidence.
Total Addressable Market (TAM)
The global mRNA therapeutics and vaccines market is projected to reach over USD 100 billion by 2030. CureVac's positioning is such that they are a relatively small player compared to market leaders. The successful execution of their pipeline is vital.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA technology platform
- Experienced management team
- Established research and development infrastructure
- Partnerships with leading pharmaceutical companies
Weaknesses
- Failed late-stage COVID-19 vaccine trial
- Delayed product development timelines
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expansion into new therapeutic areas (e.g., oncology)
- Strategic partnerships and collaborations
- Advancements in mRNA technology
- Growing demand for mRNA therapeutics and vaccines
Threats
- Intense competition from established players
- Regulatory hurdles and approval processes
- Manufacturing challenges and scalability
- Patent disputes and intellectual property risks
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- PFE
Competitive Landscape
CureVac faces significant competition from companies like Moderna and BioNTech, which have a head start in the mRNA space. CureVac needs to demonstrate technological advantages or focus on niche markets to differentiate itself.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the lack of approved products.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline programs. Analyst estimates vary widely.
Recent Initiatives: Focusing on oncology and other therapeutic areas, streamlining operations, and seeking strategic partnerships.
Summary
CureVac NV is an mRNA-based biopharmaceutical company facing significant challenges after the setback with its COVID-19 vaccine program. While the company has a proprietary technology platform and partnerships, it is behind market leaders. Future success hinges on the execution of its pipeline and strategic initiatives. The company needs to closely manage its cash flow and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions are subject to change, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 825 | Website https://www.curevac.com |
Full time employees 825 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.